Core Insights - Aadi Bioscience will halt the PRECISION1 trial due to its inability to meet the efficacy threshold for accelerated approval, focusing instead on its commercial product FYARRO® for PEComa treatment [1][2][3] - The company plans to preserve cash by reducing R&D headcount by 80% and pausing new patient enrollment in ongoing Phase 2 trials, extending its cash runway into at least the second half of 2026 [2][3] Company Focus - Aadi's marketed product, FYARRO®, is the only preferred treatment for advanced malignant PEComa, generating sales of $6.2 million in Q2 [2] - The company will continue dosing previously enrolled patients in two ongoing Phase 2 trials for advanced endometrial cancer and neuroendocrine tumors, which have sufficient patient enrollment to assess initial efficacy signals [2] Strategic Review - Aadi is conducting a comprehensive strategic review to maximize shareholder value and has engaged an advisory firm to explore options [3] - The company acknowledges the contributions of investigators and patients involved in the PRECISION1 trial while emphasizing the need for immediate actions to preserve cash [3]
Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates